Preferred Label : recombinant fusion proteins;

MeSH definition : Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.;

MeSH synonym : proteins, recombinant fusion; fusion proteins, recombinant; Recombinant Fusion Protein; Fusion Protein, Recombinant; Protein, Recombinant Fusion;

MeSH hyponym : chimeric proteins, recombinant; hybrid proteins, recombinant; Proteins, Recombinant Hybrid; Recombinant Hybrid Proteins; Proteins, Recombinant Chimeric; Recombinant Chimeric Proteins; Recombinant Hybrid Protein; Hybrid Protein, Recombinant; Protein, Recombinant Hybrid; Recombinant Chimeric Protein; Chimeric Protein, Recombinant; Protein, Recombinant Chimeric;

MeSH annotation : do not confuse with MEMBRANE FUSION PROTEINS; VIRAL FUSION PROTEINS; MUTANT CHIMERIC PROTEINS; or ONCOGENE PROTEINS, FUSION;

Wikipedia link : https://en.wikipedia.org/wiki/Recombinant fusion proteins;

Is substance : O;

Details


Main resources

You can consult :

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

https://ansm.sante.fr/tableau-marr/aflibercept
2025
false
false
false
France
French
guidelines for drug use
patients guideline
aflibercept
recombinant fusion proteins
receptors, vascular endothelial growth factor
Drug-Related side effects and adverse reactions
signs and symptoms
intravitreal injections
video recording
intravitreal injections
sound

---
https://ansm.sante.fr/tableau-acces-derogatoire/sotatercept
2025
false
false
false
France
French
sotatercept
recombinant fusion proteins
Pulmonary Arterial Hypertension
drug information
Pulmonary arterial hypertension WHO functional class III
Pulmonary arterial hypertension WHO functional class II
insurance, health, reimbursement
adult
sotatercept

---
https://ansm.sante.fr/tableau-marr/romiplostim
2024
false
false
false
France
French
injections, subcutaneous
romiplostim
risk management
romiplostim
guidelines for drug use
child
adult
patients guideline
clinical tool
home nursing
drug dosage calculations
self administration
receptors, fc
recombinant fusion proteins
thrombopoietin

---
https://www.has-sante.fr/jcms/p_3563529/fr/altuvoct-efanesoctocog-alfa-hemophilie
2024
false
false
false
France
hemorrhage
hemorrhage
treatment outcome
insurance, health, reimbursement
recombinant fusion proteins
Efanesoctocog Alfa
adult
adolescent
child
infant, newborn
infant
injections, intravenous
evaluation of the transparency committee
hemophilia A

---
https://www.has-sante.fr/jcms/p_3281010/fr/reblozyl-25-ss-thalassemie-luspatercept
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
anemia
beta-Thalassemia
blood transfusion
Transfusion dependent anaemia
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional release solution for injection (clinical drug)
injections, subcutaneous
hematinics
luspatercept
evaluation of the transparency committee
luspatercept
Reblozyl
immunoglobulin fc fragments
recombinant fusion proteins
activin receptors, type ii

---
https://ansm.sante.fr/informations-de-securite/eylea-40-mg-ml-aflibercept-en-injection-intravitreenne-risque-plus-eleve-daugmentation-de-la-pression-intraoculaire-a-la-suite-de-lutilisation-de-la-seringue-preremplie
2021
false
false
false
France
French
pharmacovigilance note
intravitreal injections
aflibercept
ocular hypertension
aflibercept
Pre-filled Syringe
drug compounding
intravitreal injections
aflibercept
guidelines for drug use
continuity of patient care
Inappropriate preparation of medication
recombinant fusion proteins
receptors, vascular endothelial growth factor
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
https://ansm.sante.fr/tableau-atu-rtu/zolgensma-2-x-1013-genomes-de-vecteur-ml-solution-pour-perfusion
2021
false
true
false
France
French
Onasemnogene Abeparvovec
Onasemnogene Abeparvovec
summary of product characteristics
package leaflet
guidelines for drug use
onasemnogene abeparvovec
spinal muscular atrophies of childhood
HMN (Hereditary motor neuropathy) proximal type I
infusions, intravenous
onasemnogene abeparvovec-xioi
Zolgensma
biological products
recombinant fusion proteins

---
https://ansm.sante.fr/informations-de-securite/zolgensma-r-onasemnogene-abeparvovec-risque-de-microangiopathie-thrombotique
2021
false
false
false
France
French
pharmacovigilance note
Onasemnogene Abeparvovec
onasemnogene abeparvovec
thrombotic microangiopathies
gene therapy
spinal muscular atrophies of childhood
infusions, intravenous
guidelines for drug use
drug monitoring
continuity of patient care
infant
onasemnogene abeparvovec-xioi
genetic therapy
Zolgensma
biological products
recombinant fusion proteins

---
https://www.ema.europa.eu/en/medicines/human/EPAR/elzonris
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
tagraxofusp
tagraxofusp
tagraxofusp
antineoplastic agents
antineoplastic agents
orphan drug production
adult
Blastic Plasmacytoid Dendritic Cell Neoplasm
infusions, intravenous
product surveillance, postmarketing
pregnancy
breast feeding
interleukin-3 receptor alpha subunit
drug evaluation, preclinical
recombinant fusion proteins
recombinant fusion proteins

---
https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
luspatercept
luspatercept
luspatercept
hematinics
hematinics
orphan drug production
anemia
myelodysplastic syndromes
beta-Thalassemia
injections, subcutaneous
product surveillance, postmarketing
Transfusion dependent anemia
adult
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional release solution for injection (clinical drug)
immunoglobulin fc fragments
recombinant fusion proteins
activins
immunoglobulin fc fragments
recombinant fusion proteins
activins

---
https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Onasemnogene abeparvovec (substance)
Onasemnogene abeparvovec (substance)
gene therapy
spinal muscular atrophies of childhood
muscular atrophy, spinal
mutation
orphan drug production
infusions, intravenous
SMN complex proteins
onasemnogene abeparvovec
Product containing only onasemnogene abeparvovec in parenteral dose form (medicinal product form)
product surveillance, postmarketing
SMN1 Gene
SMN2 Gene
drug evaluation, preclinical
infant
child, preschool
HMN (Hereditary motor neuropathy) proximal type I
onasemnogene abeparvovec-xioi
genetic therapy
spinal muscular atrophies of childhood
Zolgensma
biological products
recombinant fusion proteins

---
https://www.has-sante.fr/jcms/p_3151450/fr/nplate
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
romiplostim
child
romiplostim
infant
purpura, thrombocytopenic, idiopathic
chronic disease
injections, subcutaneous
receptors, thrombopoietin
evaluation of the transparency committee
receptors, fc
recombinant fusion proteins
thrombopoietin

---
https://www.has-sante.fr/jcms/p_3218744/fr/idelvion
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
albutrepenonacog alfa
coagulation factor IX
hemorrhage
hemorrhage
hemophilia B
evaluation of the transparency committee
factor IX
recombinant fusion proteins
serum albumin

---
https://www.has-sante.fr/jcms/p_3225392/fr/trulicity
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
injections, subcutaneous
hypoglycemic agents
adult
drug therapy, combination
Product containing only dulaglutide (medicinal product)
evaluation of the transparency committee
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins

---
https://www.has-sante.fr/jcms/p_3224937/fr/zolgensma
2020
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
Onasemnogene abeparvovec (substance)
evaluation of the transparency committee
5q spinal muscular atrophy
spinal muscular atrophies of childhood
gene therapy
orphan drug production
infusions, intravenous
SMN1 Gene
mutation
HMN (Hereditary motor neuropathy) proximal type I
infant
Product containing only onasemnogene abeparvovec in parenteral dose form (medicinal product form)
onasemnogene abeparvovec
onasemnogene abeparvovec-xioi
genetic therapy
Zolgensma
biological products
recombinant fusion proteins

---
https://www.usherbrooke.ca/baladocritique/archives/episode-26-etude-rewind/
2019
false
false
false
false
Canada
immunoglobulin fc fragments
glucagon-like peptides
recombinant fusion proteins
cardiovascular diseases
treatment outcome
hypoglycemic agents
Glucagon-Like Peptide-1 Receptor
sound
diabetes mellitus, type 2
dulaglutide

---
https://www.has-sante.fr/portail/jcms/c_2800955/fr/place-dans-la-strategie-therapeutique-de-lucentis-eylea-et-de-leurs-comparateurs-cliniquement-pertinents-dans-la-forme-neovasculaire-humide-de-la-dmla
2017
false
false
false
France
French
evaluation of the transparency committee
intravitreal injections
wet macular degeneration
comparative effectiveness research
vascular endothelial growth factor a
Ranibizumab
ranibizumab
treatment outcome
aflibercept
aflibercept
Bevacizumab
angiogenesis inhibitors
risk management
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
diabetes mellitus, type 2
review of literature
consensus
GLP-1 Mimetics
treatment outcome
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
metformin
hypoglycemic agents
hypoglycemic agents
glimepiride
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
sulfonylurea compounds
comparative effectiveness research
arterial pressure
insulin
thyroid neoplasms
pancreatitis
Injection Site Reaction
cardiovascular diseases
practice guidelines as topic
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
peptides
venoms
peptides
venoms
thiazolidinediones
Pioglitazone
Exenatide
Exenatide

---
http://www.has-sante.fr/portail/jcms/c_2671791/fr/eylea
http://www.has-sante.fr/portail/jcms/c_2671791/fr/eylea-aflibercept-anti-vegf
2016
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
adult
treatment outcome
aflibercept
aflibercept
aflibercept
intravitreal injections
choroidal neovascularization
myopia
visual acuity
vision disorders
insurance, health, reimbursement
vascular endothelial growth factors
recombinant fusion proteins
receptors, vascular endothelial growth factor
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
https://www.ema.europa.eu/medicines/human/EPAR/Alprolix
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
product surveillance, postmarketing
coagulation factor IX
orphan drug production
hemophilia B
hemorrhage
hemorrhage
injections, intravenous
factor IX Fc fusion protein
factor IX Fc fusion protein
pregnancy
breast feeding
adult
child
drug evaluation, preclinical
Eftrenonacog alfa (substance)
factor IX
immunoglobulin fc fragments
recombinant fusion proteins
factor IX
immunoglobulin fc fragments
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2617853/fr/elocta
http://www.has-sante.fr/portail/jcms/c_2617853/fr/elocta-efmoroctocog-alfa-facteur-viii
2016
false
false
false
France
French
treatment outcome
factor VIII-Fc fusion protein
factor VIII-Fc fusion protein
coagulation factor VIII
hemophilia A
hemorrhage
hemorrhage
orphan drug production
injections, intravenous
evaluation of the transparency committee
adult
adolescent
child
guidelines for drug use
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2589764/fr/eylea
2016
false
France
French
macular edema
retinal vein occlusion
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2621689/fr/strensiq
2016
false
false
false
France
French
treatment outcome
asfotase alfa
asfotase alfa
hypophosphatasia
enzyme replacement therapy
orphan drug production
injections, subcutaneous
asfotase alfa
evaluation of the transparency committee
insurance, health, reimbursement
Product containing asfotase alfa in parenteral dose form (medicinal product form)
alkaline phosphatase
immunoglobulin G
recombinant fusion proteins
alkaline phosphatase
immunoglobulin G
recombinant fusion proteins

---
Summary Basis of Decision (SBD) for Trulicity
Dulaglutide, 0.75 mg/0.5 mL and 1.5 mg/0.5 mL, solution, subcutaneous injection
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00244
2016
false
false
false
Canada
French
English
treatment outcome
summary of product characteristics
immunoglobulin fc fragments
recombinant fusion proteins
drug approval
hypoglycemic agents
hypoglycemic agents
glucagon-like peptides
adult
diabetes mellitus, type 2
drug therapy, combination
injections, subcutaneous
aged
Glycated Hemoglobin
drug evaluation, preclinical
canada
metformin
sulfonylurea compounds
insulin
Glucagon-Like Peptide-1 Receptor
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
dulaglutide
dulaglutide

---
http://www.has-sante.fr/portail/jcms/c_2025589/fr/eylea
http://www.has-sante.fr/portail/jcms/c_2025589/fr/eylea-aflibercept-anti-vegf
2015
false
France
French
macular edema
guidelines for drug use
diabetic retinopathy
diabetes complications
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins

---
https://www.ema.europa.eu/medicines/human/EPAR/Strensiq
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
asfotase alfa
asfotase alfa
hypophosphatasia
enzyme replacement therapy
orphan drug production
injections, subcutaneous
product surveillance, postmarketing
drug monitoring
pregnancy
breast feeding
drug evaluation, preclinical
asfotase alfa
Product containing asfotase alfa in parenteral dose form (medicinal product form)
alkaline phosphatase
immunoglobulin G
recombinant fusion proteins
alkaline phosphatase
immunoglobulin G
recombinant fusion proteins

---
https://www.ema.europa.eu/medicines/human/EPAR/Trulicity
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
immunoglobulin fc fragments
recombinant fusion proteins
drug approval
europe
hypoglycemic agents
hypoglycemic agents
glucagon-like peptides
adult
diabetes mellitus, type 2
drug therapy, combination
injections, subcutaneous
Pre-filled Pen Syringe
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
Glycated Hemoglobin
drug evaluation, preclinical
Prefilled Syringe Dosage Form
Glucagon-Like Peptide-1 Receptor
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
dulaglutide
dulaglutide

---
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity-dulaglutide-antidiabetique
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
drug therapy, combination
insulins
dulaglutide
dulaglutide
hypoglycemic agents
hypoglycemic agents
glucagon-like peptide 1
diabetes mellitus, type 2
metformin
adult
injections, subcutaneous
dulaglutide
dulaglutide
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00190
2015
false
false
false
false
Canada
French
drug information
Product containing asfotase alfa in parenteral dose form (medicinal product form)
asfotase alfa
asfotase alfa
alkaline phosphatase
immunoglobulin G
recombinant fusion proteins

---
https://www.ema.europa.eu/medicines/human/EPAR/Elocta
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
factor VIII-Fc fusion protein
factor VIII-Fc fusion protein
hemophilia A
hemorrhage
hemorrhage
orphan drug production
product surveillance, postmarketing
injections, intravenous
pregnancy
breast feeding
drug evaluation, preclinical
coagulation factor VIII
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins

---
Summary Basis of Decision (SBD) for Eloctate
Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein, 250, 500, 750, 1,000, 1,500, 2,000, 3,000 IU/vial, powder for solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00210
2014
false
false
false
Canada
French
English
drug information
adult
child
hemophilia A
hemorrhage
factor VIII
factor VIII
coagulation factor VIII
coagulants
coagulants
immunoglobulin fc fragments
immunoglobulin fc fragments
recombinant fusion proteins
recombinant fusion proteins
drug approval
canada
treatment outcome
chemoprevention
hemorrhage

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60089217
2014
false
false
false
France
French
package leaflet
summary of product characteristics
aflibercept
perfusion
perfusion, nos
solution, nos
aflibercept
solutions
perfusion
solutions
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
http://www.has-sante.fr/portail/jcms/c_1751177/fr/eylea
2014
false
France
French
macular edema
retinal vein occlusion
guidelines for drug use
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
randomized controlled trials as topic
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_1554433/fr/eylea
2013
false
France
French
guidelines for drug use
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
wet macular degeneration
aflibercept
vascular endothelial growth factor a
Placenta Growth Factor
treatment outcome
randomized controlled trials as topic
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins
pregnancy proteins
comparative study

---
https://www.ema.europa.eu/medicines/human/EPAR/Simulect
2012
false
United Kingdom
English
French
syndication feed
recombinant fusion proteins
immunosuppressive agents
graft rejection
graft rejection
immunosuppressive agents
kidney transplantation
adult
child
drug therapy, combination
Interleukin-2
basiliximab
drug evaluation
summary of product characteristics
package leaflet
Basiliximab
Basiliximab

---
https://www.ema.europa.eu/medicines/human/EPAR/Nplate
2012
United Kingdom
English
French
syndication feed
recombinant fusion proteins
recombinant fusion proteins
thrombopoietin
thrombopoietin
splenectomy
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug storage
drug compounding
drug labeling
romiplostim
romiplostim
orphan drug production
drug approval
treatment outcome
receptors, fc
receptors, fc
adult
purpura, thrombocytopenic, idiopathic
injections, subcutaneous
romiplostim
receptors, fc
recombinant fusion proteins
thrombopoietin
drug evaluation
summary of product characteristics

---
This medicine is now withdrawn from use in the European Union
https://www.ema.europa.eu/medicines/human/EPAR/rilonacept-regeneron-previously-arcalyst
2012
false
United Kingdom
French
English
syndication feed
Product containing rilonacept (medicinal product)
orphan drug production
rilonacept
rilonacept
recombinant fusion proteins
recombinant fusion proteins
drug approval
drug labeling
treatment outcome
drug evaluation, preclinical
drug compounding
cryopyrin-associated periodic syndromes
adult
adolescent
injections, subcutaneous
drug interactions
pregnancy
breast feeding
Interleukin-1alpha
Interleukin-1beta
rilonacept
recombinant fusion proteins
drug evaluation
summary of product characteristics
package leaflet

---
https://www.ema.europa.eu/medicines/human/EPAR/Eylea
2012
false
United Kingdom
English
French
aflibercept
drug approval
europe
treatment outcome
aflibercept
adult
wet macular degeneration
summary of product characteristics
package leaflet
drug evaluation
syndication feed
vascular endothelial growth factor a
Placenta Growth Factor
intravitreal injections
recombinant fusion proteins
recombinant fusion proteins
pregnancy
breast feeding
fertility
randomized controlled trials as topic
drug evaluation, preclinical
pregnancy proteins
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
comparative study
aflibercept

---
http://www.meddispar.fr/medicaments/3598558
2010
France
French
injections
drug prescriptions
legislation, drug
thrombopoietin
receptors, fc
recombinant fusion proteins
romiplostim
continuity of patient care
romiplostim
drug information

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Amevive-Fr.pdf
2005
Canada
French
psoriasis
recombinant fusion proteins
alefacept
recombinant fusion proteins
drug evaluation
Alefacept

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.